Syngene International reports a 2% year-on-year increase in revenue for Q2 FY26, reaching ₹911 Crore. First half revenue grew by 6%. The company won its first contract for a global phase III clinical trial, and is building a new GMP bioconjugation suite to strengthen capabilities in new modalities.
Financial Performance
In Q2 FY26, Syngene International’s revenue from operations increased by 2% year-on-year to ₹911 Crore. Reported revenue also grew by 2%. However, EBITDA decreased by 18%.
For the first half of FY26, revenue from operations increased by 6%, while reported revenue also showed a similar increase. EBITDA saw a slight decrease of 2%.
Key Financial Figures (₹ in Crores)
Q2 FY26:
- Revenue from Operations: 911
- Reported Revenue: 926
- EBITDA: 215
- PAT (before exceptional items): 67
H1 FY26:
- Revenue from Operations: 1,785
- Reported Revenue: 1,818
- EBITDA: 439
- PAT (before exceptional items): 154
Strategic Developments
Syngene secured its first global phase III clinical trial contract from a U.S.-based biotech company. This trial will involve patient recruitment across clinical sites in both the U.S. and India.
The company is expanding its biologics facility in Bengaluru to include a GMP bioconjugation suite, enhancing its capabilities in manufacturing Antibody Drug Conjugates (ADCs). This positions Syngene among a select group of CRDMOs offering full-service ADC capabilities.
Sustainability Recognition
Syngene’s laboratories achieved the highest level ‘Green Certification’ from My Green Lab (MGL), with a score exceeding 94%. The company’s EcoVadis 2025 score rose to 74/100, placing it in the 91st percentile globally for sustainability practices.
Source: BSE
